Article
USPTO Institutes Four IPRs Challenging Janssen’s Golimumab Method-of-Treatment Patents
The U.S. Patent and Trademark Office has granted institution in four inter partes review proceedings challenging Janssen Biotech's golimumab method-of-treatment patents, finding that petitioners demonstrated a reasonable likelihood of prevailing on at least one challenged claim. These IPR proceedings run parallel to ongoing BPCIA litigation between Janssen and biosimilar developers Accord BioPharma and Bio-Thera Solutions.
Goodwin Procter LLP